IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma
China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...
Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...
RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis
China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...
NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million
Shenzhen-based XtalPi Holdings Limited (HKG: 2228) announced plans to acquire a 90% stake in Re...
Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...
Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval
China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...
J&J’s Tremfya Approved for Ulcerative Colitis in China
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...
China’s CDE Reveals 93rd Batch of Reference Preparations for GQCE
China’s Center for Drug Evaluation (CDE) has released the 93rd batch of reference preparations for...
NHC Issues Guidelines for Geriatric Medicine Departments Construction and Management
The National Health Commission (NHC) this week released the “Guidelines for the Construction and Management...
Takeda Reports 2.8% Revenue Growth in Fiscal 2024, Driven by Product Sales
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) released its financial report for fiscal year 2024 (April...
Zai Lab Reports Q1 2025 Revenue Growth and Pipeline Progress
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q1 2025 financial report...
Shanghai BDgene’s BD111 Gene Therapy Advances to Phase II Clinical Trials
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has advanced its BD111 pipeline candidate into...
Prudential Hong Kong Collaborates with Foshan Fosun Chancheng Hospital for Direct Payment Services
Prudential Hong Kong Limited, a subsidiary of UK-based Prudential plc, has entered into a strategic...
Sanyou Medical Partners with CGBio to Launch Regenerative Medicine Joint Venture
China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced plans to establish a joint venture...
Hengrui Pharma Files for New Dalpiciclib Indication in Early Breast Cancer
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that a new indication approval filing...
Gilead Sciences Announces $11 Billion Investment in US Expansion
US-based major Gilead Sciences Inc. (NASDAQ: GILD) announced an additional investment of USD 11 billion...
Humanwell Healthcare Gains NMPA Approval for Giapreza Generic in Shock Therapy
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clinical trial...
Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from...
Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area
US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...